News

Cadence Adds New Class 7 (10,000) Cleanroom in Connecticut

Cadence, Inc., a leading contract manufacturer of medical devices, announced today the completion of a certified International Organization for Standardization (ISO) Class 7 (10,000) cleanroom at its Connecticut manufacturing facility.  The new cleanroom is dedicated to the production of innovative medical device components and subassemblies.

“The cleanroom opens the door to new, exciting opportunities for our manufacturing facility,” stated Chris Haddad, the Director of Operations at Cadence’s Connecticut facility.  “Adding the new cleanroom and citric passivation allows us to expand our service offerings for existing and new customers, as well as streamlines our supply chain, reduces costs, and complements our laser processing expertise.”

The new cleanroom further enhances Cadence’s portfolio as a leading, vertically integrated contract manufacturing partner of medical devices worldwide.  Cadence now offers certified cleanroom manufacturing at three of its facilities for maximum customer flexibility.

Located in Suffield, the Connecticut facility is dedicated to advanced laser processing technologies.  Virtually tour Cadence’s Connecticut facility here.

Read more here.

Recent News

10/17/2025

BRAINBox Solutions Announces Publication in JAMA Network OPEN of Major Analysis of Initial HeadSmart II Trial Concussion Patients

BRAINBox Solutions today announced the publication in JAMA Network OPEN of a major analysis of the first 1,000 patients with suspected concussion (mild traumatic brain injury or mTBI) in its pivotal, HeadSMART II study of its initial test, BRAINBox TBI, for concussion diagnosis and prognosis. The analysis, the largest of its kind, identified patient characteristics

10/16/2025

Phlow Corp. Selected by the U.S. Food and Drug Administration Commissioner’s First-Ever National Priority Voucher Pilot Program to Advance Manufacturing of a Critical Essential Medicine in America

Phlow Corp., a leading American advanced pharmaceutical contract development and manufacturing organization (CDMO), today announced that the active pharmaceutical ingredient for ketamine will be included in the first-ever U.S. Food and Drug Administration (FDA) Commissioner’s National Priority Voucher (CNPV) Pilot Program. This designation recognizes Phlow’s leadership in advancing domestic manufacturing of essential and life-changing medicines

10/16/2025

Civica To Launch Long-Acting Insulin Glargine in the US in January 2026

Non-profit pharmaceutical company Civica will launch an affordable long-acting insulin – insulin glargine-yfgn in pre-filled pens – at the lowest list price in the current long-acting insulin market. Civica insulin glargine will be available in the United States beginning January 1, 2026. In California, the product will carry the “CalRx” brand. “Civica will provide insulin